Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

Lakewood-Amedex Biotherapeutics / Equity Bottom-Up

Lakewood-Amedex Biotherapeutics (LABT US)

<ul>
<li>We are initiating coverage of Lakewood-Amedex Biotherapeutics, Inc. (LABT) with a $12.00 valuation.</li>
<li>Lakewood is a biopharmaceutical company developing a novel class of antimicrobial compounds known as Bisphosphocins , a proprietary platform designed to address one of the largest and fastest-growing challenges in modern healthcare: antimicrobial resistance (AMR).</li>
<li>The company's lead clinical candidate, Nu-3, is being developed for the treatment of infected diabetic foot ulcers (iDFU), an indication affecting millions of patients worldwide that continues to have limited treatment options.</li>
</ul>


We are initiating coverage of Lakewood-Amedex Biotherapeutics, Inc. (LABT) with a $12.00 valuation.
Lakewood is a biopharmaceutical company developing a novel class of antimicrobial compounds known as Bisphosphocins , a proprietary platform designed to address one of the largest and fastest-growing challenges in modern healthcare: antimicrobial resistance (AMR).
The company's lead clinical candidate, Nu-3, is being developed for the treatment of infected diabetic foot ulcers (iDFU), an indication affecting millions of patients worldwide that continues to have limited treatment options.


Lakewood-Amedex Biotherapeutics, Inc: Initiating Coverage - June 23, 2026

United States

Lakewood-Amedex Biotherapeutics Inc. operates as a clinical-stage biotechnology company. The Company focuses on the discovery and development of antimicrobial therapeutics for the treatment of infectious diseases, particularly those driven by antimicrobial resistance. Lakewood-Amedex Biotherapeutics operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Lakewood-Amedex Biotherapeutics, Inc: Initiating Coverage - June 23, 2026

The company's lead clinical candidate, Nu-3, is being developed for the treatment of infected diabetic foot ulcers (iDFU), an indication affecting...

Zacks Small Cap Research